David Richman, M.D.

David Paul Richman, M.D.

Specialties

Neurology - Neuroimmunology, Myasthenia Gravis

Department

Neurology

Title

  • Distinguished Professor

Reviews

To see if David Paul Richman is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

UC Davis Midtown Ambulatory Care Center

3160 Folsom Blvd, Suite 2100
Sacramento, CA 95816
Driving Directions

Primary Phone:
916-734-3588

Additional Phone Numbers

Clinic Fax: 916-734-7188
Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Philosophy of Care

Dr. Richmand approaches his practice with 3 main goals to be: evidence-based, collaborative, and straight-forward.

Clinical Interests

David P. Richman's professional interests include biochemistry and pharmacology of the nicotinic acetylcholine receptor and muscle-specific kinase (MuSK), diseases of neuromuscular transmission, myasthenia gravis, anti-MuSK myastemia, and Lambert-Eaton myasthenic syndrome, and the pathogenesis and control of autoimmune response in myasthenia gravis. Richman has coauthored an extensive list of publications and book chapters on neurological disease and related topics.

Research/Academic Interests

Dr. Richman studies the biological mechanisms that underlie diseases of the neuromuscular junction with the goal of improving their treatment. He primarily develops animal models of the diseases and test new treatments in this setting. He also assists in clinical trials of these new treatments.

Division

Neurology

Center/Program Affiliation

Center for Neuroscience
UC Davis Medical Group

Education

M.D., Johns Hopkins University School of Medicine, Baltimore MD 1969

A.B., Princeton University, Princeton NJ 1965

Internship: Internal Medicine, Albert Einstein College of Medicine, New York City NY 1969-1970

Residency

Internal Medicine, Albert Einstein College of Medicine, New York City NY 1970-1971

Neurology, Resident and Chief Resident, Massachusetts General Hospital, Boston MA 1971-1974

Fellowships

Neuroimmunology, Harvard Medical School, Boston MA 1974-1976

Board Certifications

American Board of Psychiatry and Neurology - Neurology,

Professional Memberships

American Academy of Neurology

American Association of Immunologists

American Neurological Association

Association of California Neurologists

International Society of Neuroimmunologists

Honors and Awards

UC Davis Distinguished Professor, 2017

Fellow, American Academy of Neurology, 2017

Conquer Award for Myasthenia Gravis Research, Myasthenia Gravis Foundation of Illinois, 2002

Muscular Dystrophy Association, Post-Doctoral Fellowship, 1975, 1976

Kermit Osserman Post-Doctoral Fellowship, Myasthenia Gravis Foundation, 1974, 1975

Henry Viets Student Fellowship, Myasthenia Gravis Foundation, 1968

University Scholar, Princeton University, 1962, 1963, 1964, 1965

Select Recent Publications

Nowak RJ, Coffey CS, Goldstein JM , Dimachkie MM, Benatar M, Kissel JT, Wolfe GL, Burns T, Freimer ML, Nations S, Granit V, Smith AG, Richman DP, Ciafaloni E, Al-Lozi M, Sams, Quan D, Ubogu E, Pearson B, Sharma A, Yankey JW, Uribe L, Shy ME, Amato AA, Conwit R, O’Connor KC, Hafler DA, Cudkowicz, ME, Barohn RJ, and the NeuroNEXT NN103 BeatMG Study Team.  B-cell Targeted Treatment in Myasthenia Gravis (BeatMG Study): A Phase 2 Randomized Trial of Rituximab. Submitted JAMA Neurology. 2020.

Borges LS, Richman DP. Muscle-Specific Kinase Myasthenia Gravis. Front Immunol. 2020;11(707):1-11. PMID: 32457737

Lara MS Afify A, Ellis MP, Phan CT, Richman DP, Riess. Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma. Clinical Lung Cancer. 2019;20(4):e489-e491. PMID: 31085042.

Sanders DB, Juel VC, Harati Y, Smith AG, Peltier AC, Marburger T, Lou JS, Pascuzzi RM, Richman DP, Xie T, Demmel V, Jacobus LR, Aleš KL, Jacobus DP, Dapper Study Team. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia. Muscle Nerve. 2018;57(4):561-568. PMID: 29280483.

Bissig D, Manjunath R, Brittany R, Traylor R, Richman DP and Ng KL. Acute stroke despite dabigatran anticoagulation treated with idarucizumab and intravenous tissue plasminogen activator. J Stroke Cerebrovasc Dis. 2017:e102-e104. [Epub ahead of print] PMID: 28416406.

Richman DP. Lrp4 antibodies in myasthenia gravis: Pathogenic or protective.  European J Neurol. 2016;23(11):1593-1594. PMID: 27753233.

Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87(4):419-25. PMID: 27358333.

Renton AE, Pliner HA, Carlo Provenzano et al. A genome-wide association study of myasthenia gravis. JAMA Neurol. 2015;72:396-404.

Oskarsson B, Rocke DM, Dengel K, Richman DP. Myasthenia gravis exacerbation after discontinuing mycophenolate: A single center cohort study. Neurology. 2016;86(12):1159-63. PMID: 26850977.

Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa EA, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM Jr, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM Jr, Hehir MK, Hobson-Webb LD, Howard JF Jr, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou JS, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon JS, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve. 2016 Feb;53(2):165-8.

The Huntington Study Group PHAROS Investigators. Clinical-Genetic Specificity in the Prospective Huntington At-Risk Observational Study (PHAROS): implications for clinical trials. JAMA Neurol. 2016;73(1):102-10.